Effect of miR-16 on megakaryocytic differentiation of K562 cells
SHI Jin-long1,2, LIU Feng2, HU Ying2, YUAN Yu-lin1, LU Yun2
1. Department of Anatomy, School of Basic Medicine, Wuhan University, Wuhan 430071, China;
2. Department of General and Thoracic Surgery, Jingzhou Third People's Hospital, Jingzhou 434000, China
AIM: To observe the effect of microRNA-16 (miR-16) on the megakaryocytic differentiation of K562 cells, and to explore the potential mechanism.METHODS: miR-16 was over-expressed or silenced by transfection with miR-16 mimics or inhibitor in K562 cells. The level of miR-16 was detected by real-time PCR. The expression of CD41, CD42b and CD61, as megakaryocytic differentiation markers, was detected by flow cytometry. The effect of miR-16 on the expression of myeloblastosis oncogene (MYB) was measured by Western blotting, and flow cytometry was performed to confirm whether the effect of miR-16 on expression of CD41, CD42b and CD61 was mediated by MYB.RESULTS: Transfection with miR-16 mimics dramatically elevated the level of miR-16 and the expression of CD41, CD42b and CD61 in the K562 cells. Transfection with miR-16 inhibitor decreased the level of miR-16 and the expression of CD41, CD42b and CD61 in the K562 cells (P<0.05). The expression of MYB was regulated by miR-16, and MYB silencing reversed the regulation of CD41, CD42b and CD61 induced by miR-16.CONCLUSION: miR-16 regulates the megakaryocytic differentiation of K562 cells by targeting MYB.
史金龙, 刘峰, 胡颖, 袁玉林, 卢运. 微小RNA-16对K562细胞向巨核细胞系分化的影响[J]. 中国病理生理杂志, 2015, 31(4): 585-589.
SHI Jin-long, LIU Feng, HU Ying, YUAN Yu-lin, LU Yun. Effect of miR-16 on megakaryocytic differentiation of K562 cells. Chin J Pathophysiol, 2015, 31(4): 585-589.
Fatica A, Fazi F. MicroRNA-regulated pathways in hematological malignancies:how to avoid cells playing out of tune[J]. Int J Mol Sci, 2013, 14(10):20930-20953.
[2]
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development[J]. Nat Rev Drug Discov, 2013, 12(11):847-865.
[3]
He Y, Jiang X, Chen J. The role of miR-150 in normal and malignant hematopoiesis[J]. Oncogene, 2014, 33(30):3887-3893.
[4]
Kannan M, Mohan KV, Kulkarni S, et al. Membrane array-based differential profiling of platelets during storage for 52 miRNAs associated with apoptosis[J]. Transfusion, 2009, 49(7):1443-1450.
[5]
Chung EY, Dews M, Cozma D, et al. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor micro-RNA cluster[J]. Cancer Biol Ther, 2008, 7(11):1758-1764.
Nana-Sinkam SP, Croce CM. MicroRNA in chronic lymphocytic leukemia:transitioning from laboratory-based investigation to clinical application[J]. Cancer Genet Cytogenet, 2010, 203(2):127-133.
[9]
Willimott S, Wagner SD. Post-transcriptional and post-translational regulation of Bcl2[J]. Biochem Soc Trans, 2010, 38(6):1571-1575.
[10]
Vasilatou D, Papageorgiou S, Pappa V, et al. The role of microRNAs in normal and malignant hematopoiesis[J]. Eur J Haematol, 2010, 84(1):1-16.
[11]
Pattabiraman DR, Gonda TJ. Role and potential for therapeutic targeting of MYB in leukemia[J]. Leukemia, 2013, 27(2):269-277.
[12]
Prouse MB, Campbell MM. The interaction between MYB proteins and their target DNA binding sites[J]. Biochim Biophys Acta, 2012, 1819(1):67-77.
